Talphera (TLPH)
NASDAQ:TLPH
Want to see TLPH full AI Analyst Report?
TLPH Stock Chart & Stats
$1.10
-$0.04(-6.10%)
At close: 4:00 PM EST
$1.10
-$0.04(-6.10%)
Day’s Range― - ―
52-Week Range$0.38 - $1.57
Previous CloseN/A
Volume42.81K
Average Volume (3M)2.97M
Market Cap
$56.57M
Enterprise Value$16.08M
Total Cash (Recent Filing)$21.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 19, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding51,899,647
10 Day Avg. Volume675,544
30 Day Avg. Volume2,969,035
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)2.84
Price to Sales (P/S)1726.72
P/FCF Ratio-4.25
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue16.08K
Enterprise Value/Gross Profit16.08K
Enterprise Value/Ebitda-1.13
Forecast
1Y Price Target
$3.13Price Target Upside184.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.23
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Enrollment Momentum & Near‑term Data CatalystSustained enrollment progress and a clear H2 2026 readout window materially de‑risk the pivotal program over the next 6–12 months. Completing enrollment and a rapid top‑line read (24/72 hour endpoints) shortens development timelines and strengthens the pathway toward a 2027 PMA, improving the company’s regulatory and commercial visibility.
Clinical Execution, Dosing Simplicity & KOL SupportStrong site engagement, KOL endorsement and straightforward dosing that achieves target ACT in most patients indicate operational and clinical robustness. These attributes support reproducible trial results, ease potential adoption by clinicians post‑approval, and reduce execution risk tied to complex administration or inconsistent pharmacodynamics.
Conservative Liquidity Position (cash On Hand)A cash buffer of $21.1M plus a recently closed $4.1M tranche provides near‑term funding flexibility to sustain operations and complete pivotal activities. While not a long‑term solution, this liquidity reduces immediate refinancing urgency and supports execution through upcoming operational inflection points like the topline readout.
Bears Say
Minimal Revenue And Sustained Net LossesThe company lacks a durable revenue base and reports multi‑million dollar annual losses, producing persistently negative margins and undermining self‑funding capacity. Over the medium term this elevates refinancing and dilution risks, limits reinvestment ability, and makes continued development contingent on external capital or decisive regulatory success.
Dependence On Conditional Financing TranchesRelying on milestone‑contingent tranches ties funding to successful and timely trial execution. If enrollment or data timing slips or conditions are unmet, the company could face immediate liquidity stress, forced dilution, or delayed programs, making capital availability a structural execution risk through approval and commercialization.
Rising Operating Expenses Increase Cash BurnHigher R&D and G&A, up roughly 34% year‑over‑year, structurally raise the company’s burn rate and shorten runway absent new revenue or financing. Sustained expense inflation magnifies funding needs around pivotal milestones and increases sensitivity to any delays in enrollment, readout timing, or tranche releases.
Talphera News
TLPH FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was $0.38 and its highest was $1.57 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is $56.57M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Aug 19, 2026 which is in 59 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on May 13, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.067 by $0.027.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.06.
How many shares outstanding does Talphera have?
Talphera has 51,899,647 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.067. Following the earnings report the stock price went down -0.444%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in TLPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Talphera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.13 (184.09% Upside)
$3.13 (184.09% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.75%
12-Months-Change
Fundamentals
Return on Equity
-92.98%
Trailing 12-Months
Asset Growth
101.10%
Trailing 12-Months
Company Description
Talphera
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
TLPH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and operational momentum: enrollment has surpassed the 50% milestone, sites and KOLs reported favorable feedback on dosing simplicity and stability, and management expects a rapid top-line read in H2 2026 with a PMA plan for 2027. However, the company faces higher operating expenses and depends on two conditional financing tranches (~$16M) to fund the path to potential approval, with enrollment variability and financing contingency as primary risks. Overall, positive progress is balanced against execution and financing risk, but the highlights outweigh the lowlights.View all TLPH earnings summariesTLPH Stock 12 Month Forecast
Average Price Target
$3.13
▲(184.09% Upside)
Technical Analysis
Ownership Overview
5.94% Insiders
1.48% Mutual Funds
38.89% Other Institutional Investors
52.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---